Go to the list of all blogs
Allana's Avatar
published in Blogs
Sep 25, 2026
Axcelis (ACLS) vs Veeco (VECO): Semiconductor Equipment Stocks in an AI-Driven Market

Axcelis (ACLS) vs Veeco (VECO): Semiconductor Equipment Stocks in an AI-Driven Market

Key Takeaways

  • Both ACLS and VECO are semiconductor equipment suppliers, but they serve overlapping yet distinct process niches — ion implantation versus laser annealing, deposition, and advanced packaging.
  • The two companies are pursuing a pending all-stock merger that still requires antitrust clearance from China's State Administration for Market Regulation (SAMR), tying their market positioning closely together.
  • Axcelis is showing a revenue recovery but with margins still below prior-year levels and roughly 46% of revenue tied to China.
  • Veeco recently raised its full-year revenue outlook on artificial intelligence (AI)-driven demand for advanced packaging, memory, and silicon photonics, triggering a sharp share repricing.
  • Veeco carries a "Buy" analyst consensus and a lower forward earnings multiple, while Axcelis carries a "Hold" consensus and trades at a premium forward valuation.

Setting the Scene

Semiconductor capital equipment has become one of the most closely watched corners of the market as AI infrastructure spending reshapes chip manufacturing. ACLS (Axcelis Technologies, Inc.) and VECO (Veeco Instruments Inc.) are two mid-cap equipment names that sit at the center of this theme — and, notably, are themselves engaged in a pending all-stock combination. For traders and investors weighing relative performance, momentum, and risk, this stock comparison highlights how two companies exposed to the same sector can diverge on valuation, growth drivers, and sentiment. Both experienced investors and those newer to the semiconductor space may find the contrast useful for understanding current market positioning. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.

Axcelis Technologies: Recent Results and Challenges

Axcelis Technologies designs, manufactures, and services ion implantation and other processing equipment used in semiconductor fabrication, along with a growing aftermarket business known as Customer Solutions & Innovation (CS&I). In its most recent quarter, revenue rose 10.6% year over year to $215.2 million, with non-GAAP earnings per share of $1.06 beating expectations and a book-to-bill ratio (orders relative to shipments) near 1.0x signaling steadier demand.

Despite that recovery, recent market activity has been volatile. The stock has pulled back sharply in recent weeks even as management raised its full-year revenue outlook to mid-single-digit growth. Non-GAAP gross margin slipped to 42.7% from 45.2% a year earlier, reflecting product mix and higher service costs, while systems backlog remains below prior-year levels. Sentiment has also been shaped by China exposure — roughly 46% of revenue in the latest quarter — and by a planned $35 million manufacturing facility in Pyeongtaek, Korea, aimed at diversifying capacity.

Veeco Instruments: Recent Results and Momentum

Veeco Instruments supplies semiconductor and compound semiconductor equipment across laser annealing, ion beam deposition, metal-organic chemical vapor deposition (MOCVD, a process for growing thin crystalline films), wet processing, and lithography. Its growth narrative centers on AI-linked demand for advanced packaging, high-bandwidth memory (HBM), and silicon photonics used in data-center interconnects.

Recent weeks have brought a marked shift in sentiment. Veeco delivered second-quarter revenue of $193 million with non-GAAP earnings per share of $0.33, reported accelerating order momentum, and subsequently raised its full-year revenue outlook, citing stronger AI-related equipment demand. The stock repriced sharply higher on the news after a period of choppy trading. Like Axcelis, Veeco carries meaningful customer-concentration and China-related risk, but its nearer-term catalysts have been more pronounced, reflected in a "Buy" analyst consensus and a lower forward earnings multiple relative to its trailing valuation.

Side-by-Side Analysis

The two companies differ most clearly in process focus and growth drivers. Axcelis is anchored in ion implantation, with power semiconductors (including silicon carbide) and memory as key end markets, and a substantial aftermarket revenue stream adding stability. Veeco's portfolio is broader across laser annealing, ion beam, MOCVD, wet processing, and lithography, positioning it more directly against advanced packaging and silicon photonics — areas experiencing accelerated AI-driven investment.

On valuation, the contrast is notable. Veeco trades at a lower forward earnings multiple, while Axcelis carries a premium forward valuation relative to both its industry and its own historical median. On momentum, Veeco has recently enjoyed a stronger catalyst-driven repricing, whereas Axcelis has faced margin scrutiny even as revenue recovers. Risk profiles overlap: both rely on a concentrated set of large customers and both carry China exposure, with the pending merger adding execution and regulatory-approval risk. The all-stock combination itself links the two names, as Axcelis shareholders approved the share issuance while closing awaits China's SAMR clearance.

AI-Driven Insights on the Pair

Based on observable factors, Tickeron's AI would likely lean toward VECO in the current environment, reflecting its stronger recent catalyst momentum, raised full-year outlook, more favorable consensus rating, and relatively lower forward valuation. ACLS presents a steadier demand picture and a diversified aftermarket base, but its premium multiple and still-recovering margins make its near-term trend comparatively less compelling. Because the two companies are bound by a pending merger, their relative positioning could converge as regulatory approval progresses. This assessment is probabilistic and grounded in current trend consistency, stability, and relative positioning rather than a definitive prediction. From what I see, this is important because the merger adds another layer of shared risk and potential upside.

Exploring Tickeron’s Trending AI Robots

In my research process, I often review Tickeron’s Trending AI Robots to get a sense of which automated strategies are performing best in the current market environment. The platform features hundreds of AI trading bots covering thousands of tickers, each with distinct styles, timeframes, and performance metrics. Only the strongest performers make the trending list, allowing users to evaluate win rates and trade frequency before aligning strategies with their own approach. This section has helped me identify timely ideas without replacing my own analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ACLS, VECO

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


ACLS in +4.67% Uptrend, rising for three consecutive days on September 23, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ACLS advanced for three days, in 258 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACLS's RSI Indicator exited the oversold zone, 25 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Momentum Indicator moved above the 0 level on September 23, 2026. You may want to consider a long position or call options on ACLS as a result. In 68 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for ACLS just turned positive on September 21, 2026. Looking at past instances where ACLS's MACD turned positive, the stock continued to rise in 36 of 50 cases over the following month. The odds of a continued upward trend are 72%.

ACLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for ACLS entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.365) is normal, around the industry mean (8.033). P/E Ratio (38.973) is within average values for comparable stocks, (159.834). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (0.816). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.733) is also within normal values, averaging (27.897).

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. ACLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock worse than average.

The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Lam Research Corp (NASDAQ:LRCX), Applied Materials (NASDAQ:AMAT), KLA Corporation (NASDAQ:KLAC), Teradyne (NASDAQ:TER), Ambarella (NASDAQ:AMBA).

Industry description

The electronic production equipment industry makes equipment used to produce semiconductors. Such equipment includes wafer fabrication, plasma etching and photo-resist processing equipment. The industry also makes chemical vapor deposition processing systems and photomasks, which are high-purity quartz plates that contain patterns to define integrated circuits layouts. Applied Materials, Inc., Lam Research Corporation, and KLA-Tencor Corporation are examples of electronic production equipment manufacturing companies.

Market Cap

The average market capitalization across the Electronic Production Equipment Industry is 62.72B. The market cap for tickers in the group ranges from 326.86K to 657.13B. ASMLF holds the highest valuation in this group at 657.13B. The lowest valued company is AVSR at 326.86K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Production Equipment Industry was 4%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 27%. COHU experienced the highest price growth at 16%, while TRT experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Electronic Production Equipment Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was 11% and the average quarterly volume growth was -44%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 35
Price Growth Rating: 47
SMR Rating: 71
Profit Risk Rating: 62
Seasonality Score: -33 (-100 ... +100)
View a ticker or compare two or three
ACLS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of semiconductor equipment

Industry ElectronicProductionEquipment

Industry
Electronic Production Equipment
Address
108 Cherry Hill Drive
Phone
+1 978 787-4000
Employees
1515
Web
https://www.axcelis.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.